Organic Chemical
European Commission Revokes Marketing Authorization for Ocaliva, a Liver Disease Drug, Amid Regulatory Dispute
Ocaliva, European Commission, Marketing Authorization, Liver Disease, Primary Biliary Cholangitis (PBC), Advanz Pharma
Novartis Invests $1 Billion in PTC Therapeutics’ Huntington’s Disease Program
Novartis, PTC Therapeutics, Huntington’s disease, Phase 2 drug, global license agreement, collaboration, upfront payment, milestone payments.
Novartis Announces 139 Layoffs in New Jersey Amid Ongoing Restructuring Efforts
Novartis, layoffs, New Jersey, restructuring, pharmaceutical industry
Novartis Announces 139 Job Cuts in New Jersey Amid Commercial Refocus
Novartis, job cuts, New Jersey, commercial refocus, restructuring
PTC Therapeutics Discontinues Utreloxastat Program Following Phase 2 ALS Trial Failure
PTC Therapeutics, Utreloxastat, ALS, Phase 2 Trial, CardinALS Study, Amyotrophic Lateral Sclerosis
Biopharma Companies Continue Layoffs: Novartis, Recursion, and Kronos Reduce Staff Amid Industry Restructuring
Biopharma layoffs, Novartis restructuring, Recursion, Kronos, pharmaceutical industry, workforce reduction, cost-cutting measures
FDA Approves BridgeBio’s Attruby for ATTR-CM, Offering New Hope for Patients
Attruby, BridgeBio, ATTR-CM, FDA approval, transthyretin amyloid cardiomyopathy, acoramidis, TTR stabilizer
Axsome Therapeutics Narcolepsy Drug AXS-12 Achieves Phase III Success, Paving Way for US FDA Filing
Axsome Therapeutics, AXS-12, narcolepsy, Phase III trial, ENCORE trial, FDA filing, NDA
FDA Approves Attruby (Acoramidis) for ATTR-CM, Offering New Hope for Patients with Transthyretin Cardiac Amyloidosis
Attruby, Acoramidis, FDA Approval, ATTR-CM, Transthyretin Cardiac Amyloidosis, BridgeBio Pharma, Heart Disease Treatment
Lexicon Pharmaceuticals Shifts Focus to Clinical Development Following Zynquista Setbacks
Lexicon Pharmaceuticals, Zynquista, FDA, Clinical Development, Restructuring, R&D Pipeline, LX9211, Sotagliflozin, LX9851